Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001301045 | SCV001490202 | uncertain significance | Peroxisome biogenesis disorder 2B | 2022-05-29 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 564 of the PEX5 protein (p.Ile564Val). This variant is present in population databases (rs778897851, gnomAD 0.0009%). This variant has not been reported in the literature in individuals affected with PEX5-related conditions. ClinVar contains an entry for this variant (Variation ID: 1004355). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004651550 | SCV005153251 | uncertain significance | Inborn genetic diseases | 2024-04-01 | criteria provided, single submitter | clinical testing | The c.1690A>G (p.I564V) alteration is located in exon 15 (coding exon 14) of the PEX5 gene. This alteration results from a A to G substitution at nucleotide position 1690, causing the isoleucine (I) at amino acid position 564 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |